Mission

We are driven by our mission to develop one-time, curative genetic medicines for patients living with chronic diseases.

Pipeline

We are developing genetic therapies for Parkinson's disease, hyperlipidemia, and HBV infection.

Platforms

We have developed technology platforms to support our discovery.

• In vivo Cell Reprogramming Platform

• Epigenetic Editing Platform

People

Our team is led by pioneers of the gene editing field, experienced LNP-mRNA/AAV preclinical development and gene therapy CMC experts, and experienced biotech operation and strategy experts.

Genemagic Biosciences is dedicated to developing one-time, curative genetic medicines for patients with chronic diseases. Founded in 2021, the company is led by a world-class leadership team and is advancing a robust pipeline of genetic therapies targeting Parkinson’s disease, hyperlipidemia, and chronic hepatitis B infection. Genemagic operates offices in Zhuhai and Shanghai, China, as well as in Florida, U.S.